Drexi, a cutting-edge pharmacy benefit manager (PBM), and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), have teamed up to address one of the most pressing challenges in healthcare today: providing better access to the right drugs at affordable prices. This collaboration aims to provide employers and members even more transparent drug pricing in an industry which has been traditionally driven by hidden and unstainable costs.
“As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn’t afford them,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their medication at an affordable price. We already offer transparent, low prices to cash-pay consumers and are excited to now be working with Drexi to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective.”
Amidst the ongoing struggle of increasing drug costs that countless Americans face, companies like Drexi and Cost Plus Drugs are taking a proactive stance against this affordability crisis. Anthony Masotto, GM and EVP Pharmacy at Drexi, emphasized, “Our mission is to empower every one of our members to prioritize their health without the worry and undue burden of unaffordable medications.” Through a comprehensive and transparent approach, merged with the innovative and unmatched pricing of Cost Plus Drugs, Drexi is providing its self-funded plans with the ultimate savings opportunity. “The significance of adhering to the right medication at the right price goes beyond convenience – it’s a vital step in mitigating unexpected health complications and the associated financial strain it has on individuals and families across the country,” said Masotto
For almost a decade, Drexi has been diligently crafting an advanced platform aimed at enhancing members’ ability to make well-informed choices regarding their prescription medications. Through the collaboration with Cost Plus Drugs, Drexi now provides members with an additional channel through which they can more effectively recognize cost savings opportunities and act on them: empowering them to take back control of their healthcare spending.
Looking to the future, it is evident that game-changing collaborations such as this play a vital role in reshaping the PBM landscape. By harnessing industry expertise, essential cost-saving resources, and a shared vision, Cost Plus Drugs and Drexi are leading the charge into a fresh era of proactive pharmacy consumerism, shaking up the traditional norms.
